[go: up one dir, main page]

PT2928898T - Inibidores de beta-lactamase - Google Patents

Inibidores de beta-lactamase

Info

Publication number
PT2928898T
PT2928898T PT138611983T PT13861198T PT2928898T PT 2928898 T PT2928898 T PT 2928898T PT 138611983 T PT138611983 T PT 138611983T PT 13861198 T PT13861198 T PT 13861198T PT 2928898 T PT2928898 T PT 2928898T
Authority
PT
Portugal
Prior art keywords
beta
lactamase inhibitors
lactamase
inhibitors
Prior art date
Application number
PT138611983T
Other languages
English (en)
Original Assignee
Venatorx Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Venatorx Pharmaceuticals Inc filed Critical Venatorx Pharmaceuticals Inc
Publication of PT2928898T publication Critical patent/PT2928898T/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C07F5/025—Boronic and borinic acid compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C07F5/027—Organoboranes and organoborohydrides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C07F5/04—Esters of boric acids
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nutrition Science (AREA)
  • Dermatology (AREA)
  • Physiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
PT138611983T 2012-12-07 2013-12-05 Inibidores de beta-lactamase PT2928898T (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261734900P 2012-12-07 2012-12-07
US201361783238P 2013-03-14 2013-03-14

Publications (1)

Publication Number Publication Date
PT2928898T true PT2928898T (pt) 2021-07-05

Family

ID=50884012

Family Applications (1)

Application Number Title Priority Date Filing Date
PT138611983T PT2928898T (pt) 2012-12-07 2013-12-05 Inibidores de beta-lactamase

Country Status (16)

Country Link
US (6) US9422314B2 (pt)
EP (2) EP2928898B1 (pt)
JP (2) JP6403219B2 (pt)
KR (1) KR102147420B1 (pt)
CN (1) CN105026407B (pt)
AU (1) AU2013355110B2 (pt)
BR (1) BR112015013123B1 (pt)
CA (1) CA2893943C (pt)
ES (1) ES2878118T3 (pt)
HR (1) HRP20210879T1 (pt)
IL (1) IL239212B (pt)
PL (1) PL2928898T3 (pt)
PT (1) PT2928898T (pt)
RU (1) RU2654692C2 (pt)
WO (1) WO2014089365A1 (pt)
ZA (1) ZA201504200B (pt)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG187757A1 (en) 2010-08-10 2013-03-28 Rempex Pharmaceuticals Inc Cyclic boronic acid ester derivatives and therapeutic uses thereof
WO2013033461A1 (en) 2011-08-31 2013-03-07 Rempex Pharmaceuticals, Inc. Heterocyclic boronic acid ester derivatives and therapeutic uses thereof
US10561675B2 (en) 2012-06-06 2020-02-18 Rempex Pharmaceuticals, Inc. Cyclic boronic acid ester derivatives and therapeutic uses thereof
JP6403219B2 (ja) 2012-12-07 2018-10-10 ベナトルクス ファーマシューティカルズ，インク． ベータ−ラクタマーゼ阻害剤
US9241947B2 (en) 2013-01-04 2016-01-26 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
EP2941246A4 (en) * 2013-01-04 2016-12-21 Rempex Pharmaceuticals Inc BORONIC ACID DERIVATIVES AND THEIR THERAPEUTIC USES
US9132140B2 (en) 2013-01-04 2015-09-15 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
US9101638B2 (en) 2013-01-04 2015-08-11 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
ES2730013T3 (es) 2013-01-10 2019-11-07 Venatorx Pharmaceuticals Inc Inhibidores de betalactamasa
US9944658B2 (en) 2013-03-14 2018-04-17 VenatoRx Pharmaceuticals, Inc. Beta-lactamase inhibitors
WO2015171398A1 (en) 2014-05-05 2015-11-12 Rempex Pharmaceuticals, Inc. Salts and polymorphs of cyclic boronic acid ester derivatives and therapeutic uses thereof
LT3140310T (lt) 2014-05-05 2019-11-25 Rempex Pharmaceuticals Inc Boronato druskų sintezė ir jų panaudojimas
KR20170007448A (ko) * 2014-05-19 2017-01-18 렘펙스 파머수티클스 인코퍼레이티드 보론산 유도체 및 그의 치료적 용도
HRP20210693T1 (hr) * 2014-06-11 2021-06-11 VenatoRx Pharmaceuticals, Inc. Inhibitori beta-laktamaze
US20150361108A1 (en) * 2014-06-11 2015-12-17 VenatoRx Pharmaceuticals, Inc. Orally bioavailable beta-lactamase inhibitors
US9511142B2 (en) 2014-06-11 2016-12-06 VenatoRx Pharmaceuticals, Inc. Beta-lactamase inhibitors
CA2952968A1 (en) 2014-07-01 2016-01-07 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
WO2016081297A1 (en) 2014-11-18 2016-05-26 Rempex Pharmaceuticals, Inc. Cyclic boronic acid ester derivatives and therapeutic uses thereof
EP3233869B1 (en) 2014-12-19 2019-09-25 Rempex Pharmaceuticals, Inc. Apparatus and continuous flow process for production of boronic acid derivatives
US10336702B2 (en) 2014-12-23 2019-07-02 Bergenbio Asa Pharmaceutically active compounds
WO2016149393A1 (en) 2015-03-17 2016-09-22 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
WO2017044828A1 (en) * 2015-09-11 2017-03-16 VenatoRx Pharmaceuticals, Inc. Beta-lactamase inhibitors
WO2017100537A1 (en) 2015-12-10 2017-06-15 VenatoRx Pharmaceuticals, Inc. Beta-lactamase inhibitors
CN105801610B (zh) * 2016-04-19 2018-05-18 武汉维舜医药科技有限公司 新型广谱β-内酰胺酶抑制剂
EP3478693B1 (en) 2016-06-30 2021-07-21 Qpex Biopharma, Inc. Boronic acid derivatives and therapeutic uses thereof
WO2018027062A1 (en) 2016-08-04 2018-02-08 VenatoRx Pharmaceuticals, Inc. Boron-containing compounds
GB201613946D0 (en) * 2016-08-15 2016-09-28 Univ Oslo Compounds
IL301591B1 (en) 2017-03-06 2025-11-01 Venatorx Pharmaceuticals Inc Solid forms and combination compositions comprising a beta-lactamase inhibitor and uses thereof
TW201841642A (zh) * 2017-04-28 2018-12-01 日商大日本住友製藥股份有限公司 雜環衍生物
GB201708002D0 (en) 2017-05-18 2017-07-05 Univ Oxford Innovation Ltd ß-Lactamase inhibitors
WO2018218190A1 (en) 2017-05-26 2018-11-29 VenatoRx Pharmaceuticals, Inc. Penicillin-binding protein inhibitors
EP3630783A4 (en) 2017-05-26 2021-03-03 Venatorx Pharmaceuticals, Inc. PENICILLIN-BINDING PROTEIN INHIBITORS
BR112020007138B1 (pt) 2017-10-11 2023-03-21 Qpex Biopharma, Inc Derivados de ácido borônico, métodos de síntese, composição farmacêutica e uso dos mesmos
EP3704130A4 (en) 2017-11-01 2021-07-07 Melinta Therapeutics, Inc. SUMMARY OF BORONATE ESTERS DERIVATIVES AND ASSOCIATED USES
CA3097127A1 (en) 2018-04-20 2019-10-24 Qpex Biopharma, Inc. Boronic acid derivatives and therapeutic uses thereof
CA3098433A1 (en) 2018-04-27 2019-10-31 Sumitomo Dainippon Pharma Co., Ltd. Oxo-substituted compound
EP3802551A4 (en) * 2018-05-25 2022-03-02 Venatorx Pharmaceuticals, Inc. Penicillin-binding protein inhibitors
CN113015532B (zh) * 2018-09-12 2024-03-15 维纳拓尔斯制药公司 包含β-内酰胺酶抑制剂的组合式组合物
CN113905741B (zh) * 2019-04-02 2024-12-13 维纳拓尔斯制药公司 经口递送的β-内酰胺酶抑制剂的固体形式及其用途
JP7550421B2 (ja) * 2019-10-25 2024-09-13 住友ファーマ株式会社 オキソ置換化合物からなる医薬
PH12022550983A1 (en) 2019-10-25 2023-10-09 Sumitomo Pharma Co Ltd Novel substituted condensed ring compound
US11058695B2 (en) * 2019-11-08 2021-07-13 Myongji University Industry And Academia Cooperation Foundation Inhibitor of carbapenem-hydrolyzing class D beta-lactamases
US20230114728A1 (en) 2019-11-26 2023-04-13 VenatoRx Pharmaceuticals, Inc. Penicillin-binding protein inhibitors
JP2023538645A (ja) * 2020-08-20 2023-09-08 フェーノ・セラピューティクス・カンパニー・リミテッド ボロン酸化合物
TW202228720A (zh) * 2020-12-22 2022-08-01 波蘭商昂科艾倫迪治療法股份公司 精胺酸酶抑制劑及其使用方法
EP4301466A4 (en) * 2021-03-02 2025-08-20 Univ Case Western Reserve BETA-LACTAMASE INHIBITORS AND THEIR USES
EP4324837A4 (en) * 2021-04-13 2024-10-16 Tuojie Biotech (Shanghai) Co., Ltd. Boric acid derivative acting as beta-lactamase inhibitor
WO2023155869A1 (zh) * 2022-02-18 2023-08-24 辉诺生物医药科技（杭州）有限公司 新的硼酸类化合物的晶型及其制备方法
GB202306835D0 (en) 2023-05-09 2023-06-21 Adjutec Pharma As Therapy

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ177159A (en) 1974-04-20 1978-03-06 Beecham Group Ltd Clavulanic acid, salts, esters and preparation thereof from streptomyces clavuligerus: pharmaceutical compositions
IT1283467B1 (it) * 1996-07-19 1998-04-21 Menarini Farma Ind Derivati di cicloalcani 1,2 sostituiti come inibitori della trombina, procedimento per la loro preparazione e loro impiego in formulazioni
CN1390219A (zh) 1999-09-17 2003-01-08 艾博特股份有限两合公司 作为治疗剂的吡唑并嘧啶类
US7271186B1 (en) 2002-12-09 2007-09-18 Northwestern University Nanomolar β-lactamase inhibitors
CA2528587A1 (en) * 2003-06-10 2005-01-20 Fulcrum Pharmaceuticals, Inc. .beta.-lactamase inhibitors and methods of use thereof
RS65253B1 (sr) 2004-03-30 2024-03-29 Millennium Pharm Inc Sinteza jedinjenja estra organoborne kiseline i organoborne kiseline
CN1965838A (zh) 2005-11-17 2007-05-23 李海超 含头孢匹胺和β－内酰胺酶抑制剂的药物组合物
ES2428824T3 (es) 2005-12-07 2013-11-11 Basilea Pharmaceutica Ag Combinaciones útiles de antibióticos de monobactama con inhibidores de beta-lactamasa
CN101129382B (zh) 2006-08-25 2013-12-25 天津和美生物技术有限公司 含β-内酰胺类抗生素和缓冲组分的抗生素复方
TW200930707A (en) * 2007-11-13 2009-07-16 Protez Pharmaceuticals Inc Beta-lactamase inhibitors
US20100120715A1 (en) 2007-11-13 2010-05-13 Burns Christopher J Beta-lactamase inhibitors
AU2009206119C1 (en) * 2008-01-18 2016-05-26 Merck Sharp & Dohme Llc Beta-lactamase inhibitors
US20100292185A1 (en) 2009-05-12 2010-11-18 Burns Christopher J Beta-lactamase inhibitors
US8343944B2 (en) 2009-07-28 2013-01-01 Anacor Pharmaceuticals, Inc. Trisubstituted boron-containing molecules
SG187757A1 (en) * 2010-08-10 2013-03-28 Rempex Pharmaceuticals Inc Cyclic boronic acid ester derivatives and therapeutic uses thereof
JP5809750B2 (ja) 2011-07-26 2015-11-11 ウォックハート リミテッド β−ラクタム抗生物質、スルバクタム及びβ−ラクタマーゼ阻害薬を含む医薬組成物
SG10201601327RA (en) 2011-09-04 2016-03-30 Glytech Inc Glycosylated polypeptide and drug composition containing said polypeptide
WO2013053372A1 (en) 2011-10-13 2013-04-18 Therabor Pharmaceuticals Boronic acid inhibitors of beta-lactamases
KR101288157B1 (ko) 2011-12-07 2013-07-19 백병하 기존 세파계 항생제 및 베타 락타마제 저해제로 배합된 내성균주에 기인한 감염증의 치료 및 예방을 위한 복합항생제
JP6129203B2 (ja) 2011-12-22 2017-05-17 アレス トレーディング ソシエテ アノニム α−アミノボロン酸誘導体、選択性免疫プロテアソーム阻害剤
WO2013122888A2 (en) 2012-02-15 2013-08-22 Rempex Pharmaceuticals, Inc. Methods of treating bacterial infections
US9464098B2 (en) 2012-12-03 2016-10-11 Hoffmann-La Roche Inc. Substituted triazole boronic acid compounds
JP6403219B2 (ja) 2012-12-07 2018-10-10 ベナトルクス ファーマシューティカルズ，インク． ベータ−ラクタマーゼ阻害剤
US9101638B2 (en) 2013-01-04 2015-08-11 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
US9132140B2 (en) 2013-01-04 2015-09-15 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
EP2941246A4 (en) 2013-01-04 2016-12-21 Rempex Pharmaceuticals Inc BORONIC ACID DERIVATIVES AND THEIR THERAPEUTIC USES
ES2730013T3 (es) * 2013-01-10 2019-11-07 Venatorx Pharmaceuticals Inc Inhibidores de betalactamasa
US9944658B2 (en) 2013-03-14 2018-04-17 VenatoRx Pharmaceuticals, Inc. Beta-lactamase inhibitors
WO2015051101A1 (en) 2013-10-02 2015-04-09 Cubist Pharmaceuticals, Inc. B-lactamase inhibitor picoline salt
WO2015157618A1 (en) 2014-04-11 2015-10-15 The Texas A&M University System Novel inhibitors of the new delhi metallo beta lactamase (ndm-1)
KR20170007448A (ko) 2014-05-19 2017-01-18 렘펙스 파머수티클스 인코퍼레이티드 보론산 유도체 및 그의 치료적 용도
HRP20210693T1 (hr) * 2014-06-11 2021-06-11 VenatoRx Pharmaceuticals, Inc. Inhibitori beta-laktamaze
US9511142B2 (en) 2014-06-11 2016-12-06 VenatoRx Pharmaceuticals, Inc. Beta-lactamase inhibitors
US20150361108A1 (en) 2014-06-11 2015-12-17 VenatoRx Pharmaceuticals, Inc. Orally bioavailable beta-lactamase inhibitors
US20150361107A1 (en) * 2014-06-11 2015-12-17 VenatoRx Pharmaceuticals, Inc. Orally bioavailable beta-lactamase inhibitors
EP3189841B1 (en) 2014-09-04 2023-11-22 Shionogi & Co., Ltd. Pharmaceutical preparation comprising cephalosporin having catechol groups
EP3233869B1 (en) 2014-12-19 2019-09-25 Rempex Pharmaceuticals, Inc. Apparatus and continuous flow process for production of boronic acid derivatives
WO2017044828A1 (en) 2015-09-11 2017-03-16 VenatoRx Pharmaceuticals, Inc. Beta-lactamase inhibitors
WO2017100537A1 (en) 2015-12-10 2017-06-15 VenatoRx Pharmaceuticals, Inc. Beta-lactamase inhibitors
CN105801610B (zh) 2016-04-19 2018-05-18 武汉维舜医药科技有限公司 新型广谱β-内酰胺酶抑制剂
WO2018027062A1 (en) 2016-08-04 2018-02-08 VenatoRx Pharmaceuticals, Inc. Boron-containing compounds
IL301591B1 (en) 2017-03-06 2025-11-01 Venatorx Pharmaceuticals Inc Solid forms and combination compositions comprising a beta-lactamase inhibitor and uses thereof
WO2018218190A1 (en) 2017-05-26 2018-11-29 VenatoRx Pharmaceuticals, Inc. Penicillin-binding protein inhibitors
EP3630783A4 (en) 2017-05-26 2021-03-03 Venatorx Pharmaceuticals, Inc. PENICILLIN-BINDING PROTEIN INHIBITORS
WO2019118358A1 (en) 2017-12-11 2019-06-20 VenatoRx Pharmaceuticals, Inc. Hepatitis b capsid assembly modulators
EP3802551A4 (en) 2018-05-25 2022-03-02 Venatorx Pharmaceuticals, Inc. Penicillin-binding protein inhibitors

Also Published As

Publication number Publication date
EP2928898A1 (en) 2015-10-14
US20160326189A1 (en) 2016-11-10
AU2013355110A1 (en) 2015-07-02
BR112015013123A2 (pt) 2017-07-11
EP3922635A1 (en) 2021-12-15
JP6403219B2 (ja) 2018-10-10
US20150291630A1 (en) 2015-10-15
ES2878118T3 (es) 2021-11-18
US20250236632A1 (en) 2025-07-24
WO2014089365A1 (en) 2014-06-12
US9422314B2 (en) 2016-08-23
US10669290B2 (en) 2020-06-02
EP2928898B1 (en) 2021-04-14
HK1217334A1 (zh) 2017-01-06
JP2018184409A (ja) 2018-11-22
EP2928898A4 (en) 2016-06-29
CA2893943A1 (en) 2014-06-12
PL2928898T3 (pl) 2021-10-25
AU2013355110B2 (en) 2017-11-09
HRP20210879T1 (hr) 2021-08-20
KR20150109348A (ko) 2015-10-01
RU2015126912A (ru) 2017-01-12
JP2016502973A (ja) 2016-02-01
RU2654692C2 (ru) 2018-05-22
ZA201504200B (en) 2017-09-27
IL239212B (en) 2019-10-31
US20180194783A1 (en) 2018-07-12
US20140171390A1 (en) 2014-06-19
CN105026407A (zh) 2015-11-04
US20190225628A1 (en) 2019-07-25
IL239212A0 (en) 2015-07-30
BR112015013123B1 (pt) 2021-02-17
US8912169B2 (en) 2014-12-16
US10214547B2 (en) 2019-02-26
CN105026407B (zh) 2017-09-08
KR102147420B1 (ko) 2020-08-25
US9828391B2 (en) 2017-11-28
CA2893943C (en) 2021-03-02

Similar Documents

Publication Publication Date Title
ZA201504200B (en) Beta-lactamase inhibitors
EP2970340A4 (en) BETA-Lactamase INHIBITORS
EP2943204A4 (en) BETA-Lactamase INHIBITORS
SI2892889T1 (sl) Inhibitorske spojine
SG11201405965RA (en) Heterobicyclic compounds as beta-lactamase inhibitors
IL234845A0 (en) Isocazole as a beta-lactamase inhibitor
IL238391A (en) Rock inhibitors
ZA201506156B (en) Novel inhibitors
PT2838888T (pt) Tiadiazolidinedionas como inibidores da gsk-3
IL239153A0 (en) Substitute pyridopyrazine as an inhibitor
IL235919A0 (en) inhibitors of fbxo3
PT2912021T (pt) Inibidores de agrecanase
EP2885291A4 (en) INHIBITORS OF VEGFR3
EP2885292A4 (en) VEGFR3 INHIBITORS
PL2888228T3 (pl) Inhibitory oddziaływania CD40-TRAF6
GB201211019D0 (en) Inhibitor compounds
GB201223308D0 (en) Enzyme inhibitors
GB201210390D0 (en) Antibacterial enzyme inhibitors
GB201200094D0 (en) Antibacterial enzyme inhibitors
GB201120474D0 (en) Inhibitors